A new crop of biotech startups in China is looking to partner with global players to develop antibodies to treat life-threatening conditions like cancer. The so-called "in China for Global" model is a drastic departure from "in China for China" strategy that has been trotted out as an ideal path for years.
‘In China For Global’ Approach Fuels Chinese Biotech Forays
China's emerging role as a launch pad for global biotech ventures is slowly taking shape, fueled by ready venture capital funding and strong government support. Although capital outflow controls are tightening, the number of biotech deals will ratchet up, executives say.
